Archives

Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, today announces publication of the results of the phase II/III trial in pleural mesothelioma (DENIM) in The Lancet Oncology, one of the world’s leading scientific journals.

Highlights from the DENIM trial in pleural mesothelioma:

In the DENIM phase II/III trial, mesothelioma patients with stable disease or better after platin-pemetrexed chemotherapy received either MesoPher maintenance treatment or best supportive care.

Although the study was negative for its primary endpoint of overall survival for all patients, the data reveal important subgroups of patients who had clinically meaningful benefit from MesoPher treatment.

Analysis revealed